• Strategic Use of nor-Binaltorphimine in Opioid Circuit Resea

  2026-08-05

  This thought-leadership article explores how nor-Binaltorphimine dihydrochloride advances the mechanistic dissection of κ-opioid receptor pathways, with strategic insights for translational pain and addiction research. Drawing on recent circuit-level discoveries and practical workflow guidance, the discussion bridges experimental design with clinical context, empowering researchers to address the complexity of opioid signaling using best-in-class tools from APExBIO.

• SB203580: Optimizing p38 MAPK Signaling Pathway Research Wor

  2026-08-05

  SB203580, a selective p38 MAPK inhibitor, empowers researchers to dissect cellular stress and inflammation pathways with precision. This guide spotlights experimental enhancements, troubleshooting tactics, and cross-domain insights from recent regenerative medicine breakthroughs, enabling robust, reproducible results using APExBIO's high-purity reagent.

• Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2

  2026-08-04

  This study identifies Merbromin as a potent, selective mixed-type inhibitor of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro). The findings provide valuable mechanistic insight into protease inhibition and suggest Merbromin as a promising scaffold for antiviral drug development.

• EPZ-6438: EZH2 Inhibitor Protocols for Epigenetic Cancer Mod

  2026-08-04

  EPZ-6438 from APExBIO advances epigenetic cancer research with precise, reproducible inhibition of EZH2 and H3K27 trimethylation. This guide details protocol enhancements, troubleshooting, and cutting-edge workflows for robust results in malignant rhabdoid tumor and HPV-associated cervical cancer models.

• Circulating GPNMB Model Predicts Immunotherapy Response in E

  2026-08-03

  This study introduces a multimodal model leveraging circulating GPNMB and tumor microenvironment features to predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). By dissecting the mechanisms of GPNMB-driven CD8+ T cell exhaustion and integrating spatial and clinical data, the research provides a clinically actionable framework for precision immunotherapy stratification.

• Small Molecule-Enhanced Generation of Pancreatic Ductal Orga

  2026-08-03

  Liao et al. present a protocol using a small molecule cocktail to markedly improve the efficiency and stability of pancreatic ductal organoid (PDO) generation. This advance enables robust, long-term cultures that better model ductal cell diversity, supporting research in pancreatic disease biology and drug screening.

• Aconitase Activity Colorimetric Assay Kit: Precision in TCA

  2026-08-02

  Unlock rapid, high-sensitivity quantification of iron-sulfur protein aconitase activity with the Aconitase Activity Colorimetric Assay Kit. Designed for nuanced oxidative stress studies and immunometabolic workflows, this kit streamlines experimental throughput while delivering robust, reproducible results.

• BCECF-AM: Optimizing Intracellular pH Measurement Workflows

  2026-08-01

  BCECF-AM stands out as a ratiometric, cell-permeable dye enabling advanced intracellular pH measurement in mammalian and plant systems. This guide delivers actionable, protocol-driven insights and troubleshooting steps for extracting high-fidelity data from complex cell biology assays. Discover how APExBIO’s high-purity BCECF-AM can transform both routine and cutting-edge research.

• Targeted SPP1 Inhibition in Tumor-Associated Macrophages Red

  2026-07-31

  This study establishes that specific small-molecule inhibition of SPP1 in tumor-associated macrophages (TAMs) leads to significant tumor shrinkage in murine models. The research introduces a phenotypic screening approach to identify effective SPP1 modulators and demonstrates the therapeutic potential of a TAM-targeted nanoformulation.

• MLN4924 and Neddylation: Catalyzing Next-Gen Cancer Research

  2026-07-31

  This article provides translational researchers with a mechanistic and strategic roadmap for leveraging MLN4924—a potent NEDD8-activating enzyme (NAE) inhibitor—in cancer biology. Integrating recent insights into stress response signaling and the evolving role of the ubiquitin-proteasome system, it offers actionable guidance for experimental design, protocol optimization, and translational progression, while highlighting APExBIO's MLN4924 as a benchmark tool. The discussion bridges foundational biology with the latest findings on ribotoxic stress, situating MLN4924 at the intersection of cellular stress management and therapeutic innovation.

• Fenipentol (1-Phenyl-1-pentanol): Evidence, Mechanisms, and

  2026-07-30

  Fenipentol, also known as 1-Phenyl-1-pentanol, is a bioactive molecule with documented roles as a choleretic agent and modulator of gastrointestinal and hepatic physiology. Its verified mechanisms include estrogen receptor α interaction and robust effects on bile and pancreatobiliary secretions. This article consolidates current evidence, practical workflow parameters, and boundaries for research usage.

• Ajugol Enhances Mitophagy to Suppress Gouty Arthritis Pyropt

  2026-07-30

  The referenced study reveals that ajugol alleviates acute gouty arthritis by promoting mitophagy and suppressing chondrocyte pyroptosis through inhibition of the PI3K/AKT/mTOR pathway. These findings highlight a mitochondrial-targeted strategy for controlling inflammation and cartilage degeneration in gouty arthritis.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Pathway

  2026-07-29

  This study identifies gramine, a natural indole alkaloid, as a selective inhibitor of triple-negative breast cancer (TNBC) cell growth by inducing ferroptosis through the CUL3-mediated ubiquitination of MTDH. The work uncovers a novel regulatory axis for ferroptosis, offering new mechanistic insights and potential avenues for targeted therapy in TNBC.

• Ertapenem Sodium Salt: Pharmacokinetics, Resistance, and Res

  2026-07-29

  Explore the unique pharmacokinetic profile and resistance implications of Ertapenem sodium salt. This in-depth review reveals how APExBIO’s compound advances both antibacterial research and the understanding of carbapenem resistance.

• Ivermectin: Broad-Spectrum Anti-Parasitic in Parasitology Re

  2026-07-28

  Ivermectin's high-purity and validated solubility profile empower cutting-edge anti-parasitic and tumor microenvironment studies. Explore advanced workflows, troubleshooting insights, and the translational impact of APExBIO’s Ivermectin for next-generation parasitology and stemness-targeted research.

16338 records 1/1090 page Next 12345 下5页 Last page